Recent advances in the development of novel mucosal adjuvants and antigen delivery systems

Human Vaccines

Volumn 6, Issue 9, 2010, Pages 706-714

  Chen, Wangxue ^a,b   Patel, Girishchandra B ^a   Yan, Hongbin ^b   Zhang, Jianbing ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b BROCK UNIVERSITY   (Canada)

Author keywords

Archaeal lipids; c di GMP; M cells; Mucosal adjuvant

Indexed keywords

3',5' CYCLIC DIGUANYLIC ACID; ADJUVANT; BACTERIAL TOXIN; BACTERIAL VECTOR; CPG OLIGODEOXYNUCLEOTIDE; ISCOM; LIPOSOME; MONOACYLGLYCEROL; NANOPARTICLE; OUTER MEMBRANE PROTEIN; PHOSPHORYL LIPID A; POLYGLACTIN; POLYSTYRENE; UNCLASSIFIED DRUG; VIROSOME; VIRUS VACCINE; VIRUS VECTOR;

CLINICAL RESEARCH; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; IMMUNIZATION; MUCOSA; MUCOSAL IMMUNITY; NONHUMAN; PROTEOLIPOSOME; REVIEW; SOCIOECONOMICS; VIRUS LIKE AGENT;

EID: 78649336859     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.9.11561     Document Type: Review

References (121)

1. Jakobsen H, Jonsdottir I. Mucosal vaccination against encapsulated respiratory bacteria - new potentials for conjugate vaccines? Scand J Immunol 2003; 58:119-28.
2. Mestecky J, Michalek SM, Moldoveanu Z, Russell MW. Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans. Behring Inst Mitt 1997; 33-43.
3. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6:148-58.
4. Singh M, O'Hagan DT. Recent advances in vaccine adjuvants. Pharm Res 2002; 19:715-28.
5. Enose Y, Ui M, Miyake A, Suzuki H, Uesaka H, Kuwata T, et al. Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV. Virology 2002; 298:306-16. (Pubitemid 35034546)
6. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 2003; 21:89-95. (Pubitemid 36588654)
7. Vyas SP, Gupta PN. Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev Vaccines 2007; 6:401-18.
8. Foxwell AR, Cripps AW, Kyd JM. Optimization of oral immunization through receptor-mediated targeting of M cells. Hum Vaccin 2007; 3:220-3.
9. Sabin AB. Strategies for elimination of poliomyelitis in different parts of the world with use of oral poliovirus vaccine. Rev Infect Dis 1984; 6:391-6.
10. Man AL, Prieto-Garcia ME, Nicoletti C. Improving M cell mediated transport across mucosal barriers: do certain bacteria hold the keys? Immunology 2004; 113:15-22.
11. Kemble G, Greenberg H. Novel generations of influenza vaccines. Vaccine 2003; 21:1789-95.
12. Lemoine D, Francotte M, Preat V. Nasal vaccines. From fundamental concepts to vaccine development. S T P pharma sciences 1998; 8:5-18.
13. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001; 14:430-45. (Pubitemid 32294678)
14. Mestecky J, Moldoveanu Z, Michalek SM, Morrow CD, Compans RW, Schafer DP, et al. Current opinions for vaccine delivery systems by mucosal routes. J Control Release 1997; 48:243-57. (Pubitemid 27401982)
15. De Magistris MT. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev 2006; 58:52-67.
16. Freytag LC, Clements JD. Mucosal adjuvants. Vaccine 2005; 23:1804-13.
17. Goyal AK, Khatri K, Mishra N, Vyas SP. New patents on mucosal delivery of vaccines. Expert Opin Ther Patents 2008; 18:1271-88.
18. Mann JF, Acevedo R, Campo JD, Perez O, Ferro VA. Delivery systems: a vaccine strategy for overcoming mucosal tolerance? Expert Rev Vaccines 2009; 8:103-12.
19. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm 2008; 364:272-80.
20. Vajdy M, Srivastava I, Polo J, Donnelly J, O'Hagan D, Singh M. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol Cell Biol 2004; 82:617-27.
21. Christensen D, Korsholm KS, Rosenkrands I, Lindenstrom T, Andersen P, Agger EM. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 2007; 6:785-96.
22. Demberg T, Robert-Guroff M. Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol 2009; 28:20-48.
23. Jones T, Cyr S, Allard F, Bellerose N, Lowell GH, Burt DS. Protollin: a novel adjuvant for intranasal vaccines. Vaccine 2004; 22:3691-7. (Pubitemid 39099644)
24. Perez O, Lastre M, Cabrera O, del Campo J, Bracho G, Cuello M, et al. New vaccines require potent adjuvants like AFPL1 and AFCo1. Scand J Immunol 2007; 66:271-7.
25. Mitragotri S. Immunization without needles. Nat Rev Immunol 2005; 5:905-16.
26. Oliveira ML, Areas AP, Ho PL. Intranasal vaccines for protection against respiratory and systemic bacterial infections. Expert Rev Vaccines 2007; 6:419-29.
27. Drane D, Gittleson C, Boyle J, Maraskovsky E. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines 2007; 6:761-72. (Pubitemid 47607851)
28. Sanders MT, Deliyannis G, Pearse MJ, McNamara MK, Brown LE. Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract. Vaccine 2009; 27:2475-82.
29. Kersten GF, Crommelin DJ. Liposomes and ISCOMS as vaccine formulations. Biochim Biophys Acta 1995; 1241:117-38.
30. Hu KF, Lovgren-Bengtsson K, Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev 2001; 51:149-59. (Pubitemid 32763079)
31. Papahadjopoulos D, Vail WJ, Jacobson K, Poste G. Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles. Biochim Biophys Acta 1975; 394:483-91.
32. Gould-Fogerite S, Kheiri MT, Zhang F, Wang Z, Scolpino AJ, Feketeova E, et al. Targeting immune response induction with cochleate and liposome-based vaccines. Adv Drug Deliv Rev 1998; 32:273-87.
33. Bracho G, Lastre M, Campo J, Zayas C, Gonzales D, Gil D, et al. Proteoliposome derived cochleate as novel adjuvant. Vaccine 2006; 24:30-1.
34. Perez O, Bracho G, Lastre M, Mora N, del Campo J, Gil D, et al. Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunol Cell Biol 2004; 82:603-10.
35. Betageri GV, Jenkins SA, Parsons DL. Liposome Drug Delivery Systems. Lancaster, PA Technomic Publishing Co., Inc 1993.
36. Gould-Fogerite S, Mannino RJ. Cochleates for induction of mucosal and systemic immune responses. In: O'Hagan DT, ed. Vaccine adjuvants: Preparation methods and research protocols. NJ: Humana Press, Inc 2000; 179-96.
37. Giri PK, Khuller GK. Is intranasal vaccination a feasible solution for tuberculosis? Expert Rev Vaccines 2008; 7:1341-56.
38. Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 2006; 80:4962-70.
39. Patel GB, Ponce A, Zhou H, Chen W. Safety of intranasally administered archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) vaccine in mice. International journal of toxicology 2008; 27:329-39.
40. Patel GB, Ponce A, Zhou H, Chen W. Structural characterization of archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) formulations prepared by different protocols and their efficacy upon intranasal immunization of mice. Journal of liposome research 2008; 18:127-43.
41. Patel GB, Zhou H, Ponce A, Chen W. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines. Vaccine 2007; 25:8622-36.
42. Kates M. Archaebacterial lipids: structure, biosynthesis and function. Biochem Soc Symp 1992; 58:51-72.
43. Sprott GD. Structures of archaebacterial membrane lipids. J Bioenerg Biomembr 1992; 24:555-66.
44. Patel GB, Sprott GD. Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems. Crit Rev Biotechnol 1999; 19:317-57.
45. Sprott GD, Dicaire CJ, Fleming LP, Patel GB. Stability of liposomes prepared from archaeobacterial lipids and phosphatidylcholine mixtures. Cells and Materials 1996; 6:143-55.
46. Sprott GD, Patel GB, Makabi-Panzu B, Tolson DL. Archaeosomes, archaeosomes containing coenzyme Q10, and other types of liposomes containing coenzyme Q10 as adjuvants and as delivery vehicles. 1997.
47. Patel GB, Chen W. Archaeosome immunostimulatory vaccine delivery system. Curr Drug Deliv 2005; 2:407-21.
48. Krishnan L, Sprott GD. Archaeosome adjuvants: immunological capabilities and mechanism(s) of action. Vaccine 2008; 26:2043-55.
49. Gould-Fogerite S, Mannino RJ. Mucosal and systemic immunization using cochleate and liposome vaccines. J Liposome Res 1996; 6:357-79.
50. Gherardi MM, Esteban M. Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol 2005; 86:2925-36.
51. Bergquist C, Lagergard T, Holmgren J. Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate. Infection and Immunity 1997; 65:1579-83.
52. Haneberg B, Herland Berstad AK, Holst J. Bacteria-derived particles as adjuvants for non-replicating nasal vaccines. Advanced drug delivery reviews 2001; 51:143-7.
53. Mestecky J, Nguyen H, Czerkinsky C, Kiyono H. Oral immunization: an update. Curr Opin Gastroenterol 2008; 24:713-9.
54. Baca-Estrada ME, Foldvari M, Snider M, Harding K, Kournikakis B, Babiuk L, Griebel P. Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses. Vaccine 2000; 18:2203-11.
55. Harokopakis E, Hajishengallis G, Michalek SM. Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system. Infect Immun 1998; 66:4299-304.
56. Vadolas J, Davies JK, Wright PJ, Strugnell RA. Intranasal immunization with liposomes induces strong mucosal immune responses in mice. Eur J Immunol 1995; 25:969-75.
57. Choquet CG, Patel GB, Beveridge TJ, Sprott GD. Stability of pressure-extruded liposomes made from archaeobacterial ether lipids. Appl Microbiol Biotechnol 1994; 42:375-84.
58. Patel GB, Agnew BJ, Deschatelets L, Fleming LP, Sprott GD. In vitro assessment of archaeosome stability for developing oral delivery systems. Int J Pharm 2000; 194:39-49.
59. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4:145-60.
60. Galperin MY. Bacterial signal transduction network in a genomic perspective. Environ Microbiol 2004; 6:552-67.
61. Ryjenkov DA, Tarutina M, Moskvin OV, Gomelsky M. Cyclic diguanylate is a ubiquitous signaling molecule in bacteria: insights into biochemistry of the GGDEF protein domain. J Bacteriol 2005; 187:1792-8.
62. Paul R, Weiser S, Amiot NC, Chan C, Schirmer T, Giese B, Jenal U. Cell cycle-dependent dynamic localization of a bacterial response regulator with a novel di-guanylate cyclase output domain. Genes Dev 2004; 18:715-27.
63. Romling U, Amikam D. Cyclic di-GMP as a second messenger. Curr Opin Microbiol 2006; 9:218-28.
64. Schirmer T, Jenal U. Structural and mechanistic determinants of c-di-GMP signalling. Nat Rev Microbiol 2009; 7:724-35.
65. Jenal U. Cyclic di-guanosine-monophosphate comes of age: a novel secondary messenger involved in modulating cell surface structures in bacteria? Curr Opin Microbiol 2004; 7:185-91.
66. Tischler AD, Camilli A. Cyclic diguanylate (c-di-GMP) regulates Vibrio cholerae biofilm formation. Mol Microbiol 2004; 53:857-69.
67. Romling U, Gomelsky M, Galperin MY. C-di-GMP: the dawning of a novel bacterial signalling system. Mol Microbiol 2005; 57:629-39.
68. Karaolis DK, Means TK, Yang D, Takahashi M, Yoshimura T, Muraille E, et al. Bacterial c-di-GMP is an immunostimulatory molecule. J Immunol 2007; 178:2171-81.
69. Yan H, KuoLee R, Tram K, Qiu H, Zhang J, Patel GB, Chen W. 3′,5′-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection. Biochem Biophys Res Commun 2009; 387:581-4.
70. Ogunniyi AD, Paton JC, Kirby AC, McCullers JA, Cook J, Hyodo M, et al. c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection. Vaccine 2008; 26:4676-85.
71. Yan H, Wang X, KuoLee R, Chen W. Synthesis and immunostimulatory properties of the phosphorothioate analogues of cdiGMP. Bioorg Med Chem Lett 2008; 18:5631-4.
72. Hu DL, Narita K, Hyodo M, Hayakawa Y, Nakane A, Karaolis DK. c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection. Vaccine 2009; 27:4867-73.
73. Karaolis DK, Newstead MW, Zeng X, Hyodo M, Hayakawa Y, Bhan U, et al. Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia. Infect Immun 2007; 75:4942-50.
74. Ebensen T, Schulze K, Riese P, Link C, Morr M, Guzman CA. The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties. Vaccine 2007; 25:1464-9.
75. Ebensen T, Schulze K, Riese P, Morr M, Guzman CA. The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant. Clin Vaccine Immunol 2007; 14:952-8.
76. McWhirter SM, Barbalat R, Monroe KM, Fontana MF, Hyodo M, Joncker NT, et al. A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med 2009; 206:1899-911.
77. Sanchez J, Holmgren J. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell Mol Life Sci 2008; 65:1347-60.
78. Lycke N. Targeted vaccine adjuvants based on modified cholera toxin. Curr Mol Med 2005; 5:591-7.
79. Heyningen SV. Cholera toxin: interaction of subunits with ganglioside GM1. Science 1974; 183:656-7.
80. Moss J, Richardson SH. Activation of adenylate cyclase by heat-labile Escherichia coli enterotoxin. Evidence for ADP-ribosyltransferase activity similar to that of choleragen. J Clin Invest 1978; 62:281-5.
81. Schulze K, Medina E, Chhatwal GS, Guzman CA. Stimulation of long-lasting protection against Streptococcus pyogenes after intranasal vaccination with non adjuvanted fibronectin-binding domain of the SfbI protein. Vaccine 2003; 21:1958-64.
82. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002; 20:2431-8.
83. Connell TD. Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins. Expert Rev Vaccines 2007; 6:821-34.
84. Eriksson A, Lycke N. The CTA1-DD vaccine adjuvant binds to human B cells and potentiates their T cell stimulating ability. Vaccine 2003; 22:185-93.
85. Agren LC, Ekman L, Lowenadler B, Nedrud JG, Lycke NY. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J Immunol 1999; 162:2432-40.
86. Areas AP, Oliveira ML, Miyaji EN, Leite LC, Aires KA, Dias WO, Ho PL. Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. Biochem Biophys Res Commun 2004; 321:192-6.
87. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363:446-8.
88. Zhang J, Li Q, Nguyen TD, Tremblay TL, Stone E, To R, et al. A pentavalent single-domain antibody approach to tumor antigen discovery and the development of novel proteomics reagents. J Mol Biol 2004; 341:161-9.
89. Zhang J, Tanha J, Hirama T, Khieu NH, To R, Tong-Sevinc H, et al. Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents. J Mol Biol 2004; 335:49-56.
90. Li S, Zheng W, Kuolee R, Hirama T, Henry M, Makvandi-Nejad S, et al. Pentabody-mediated antigen delivery induces antigen-specific mucosal immune response. Mol Immunol 2009; 46:1718-26.
91. Ohmura-Hoshino M, Yamamoto M, Yuki Y, Takeda Y, Kiyono H. Non-toxic Stx derivatives from Escherichia coli possess adjuvant activity for mucosal immunity. Vaccine 2004; 22:3751-61.
92. Renauld-Mongenie G, Mielcarek N, Cornette J, Schacht AM, Capron A, Riveau G, et al. Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis. Proc Natl Acad Sci USA 1996; 93:7944-9.
93. Haugan A, Thi Dao PX, Glende N, Bakke H, Haugen IL, Janakova L, et al. Bordetella pertussis can act as adjuvant as well as inhibitor of immune responses to non-replicating nasal vaccines. Vaccine 2003; 22:7-14.
94. Orr B, Douce G, Baillie S, Parton R, Coote J. Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice. Vaccine 2007; 25:64-71.
95. Roberts M, Bacon A, Rappuoli R, Pizza M, Cropley I, Douce G, et al. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infect Immun 1995; 63:2100-8.
96. Wilson AD, Robinson A, Irons L, Stokes CR. Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigen. Vaccine 1993; 11:113-8.
97. Owen RL. Sequential uptake of horseradish peroxidase by lymphoid follicle epithelium of Peyer's patches in the normal unobstructed mouse intestine: an ultrastructural study. Gastroenterology 1977; 72:440-51.
98. Tyrer PC, Ruth Foxwell A, Kyd JM, Otczyk DC, Cripps AW. Receptor mediated targeting of M-cells. Vaccine 2007; 25:3204-9.
99. Baumler AJ, Tsolis RM, Heffron F. The lpf fimbrial operon mediates adhesion of Salmonella typhimurium to murine Peyer's patches. Proc Natl Acad Sci USA 1996; 93:279-83.
100. Suzuki T, Yoshikawa Y, Ashida H, Iwai H, Toyotome T, Matsui H, Sasakawa C. High vaccine efficacy against shigellosis of recombinant noninvasive Shigella mutant that expresses Yersinia invasin. J Immunol 2006; 177:4709-17.
101. Londono-Arcila P, Freeman D, Kleanthous H, O'Dowd AM, Lewis S, Turner AK, et al. Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen. Infect Immun 2002; 70:5096-106.
102. Stokes MG, Titball RW, Neeson BN, Galen JE, Walker NJ, Stagg AJ, et al. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis. Infect Immun 2007; 75:1827-34.
103. Crotty S, Miller CJ, Lohman BL, Neagu MR, Compton L, Lu D, et al. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J Virol 2001; 75:7435-52.
104. Clark MA, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev 2001; 50:81-106.
105. Hussain N, Florence AT. Utilizing bacterial mechanisms of epithelial cell entry: invasin-induced oral uptake of latex nanoparticles. Pharm Res 1998; 15:153-6.
106. Gullberg E, Keita AV, Salim SY, Andersson M, Caldwell KD, Soderholm JD, et al. Identification of cell adhesion molecules in the human follicle-associated epithelium that improve nanoparticle uptake into the Peyer's patches. J Pharmacol Exp Ther 2006; 319:632-9.
107. Garinot M, Fievez V, Pourcelle V, Stoffelbach F, des Rieux A, Plapied L, et al. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release 2007; 120:195-204.
108. Rajapaksa TE, Stover-Hamer M, Fernandez X, Eckelhoefer HA, Lo DD. Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J Control Release 2009.
109. Tyrer P, Ruth Foxwell A, Kyd J, Harvey M, Sizer P, Cripps A. Validation and quantitation of an in vitro M-cell model. Biochem Biophys Res Commun 2002; 299:377-83.
110. Smith MW, Thomas NW, Jenkins PG, Miller NG, Cremaschi D, Porta C. Selective transport of microparticles across Peyer's patch follicle-associated M cells from mice and rats. Exp Physiol 1995; 80:735-43.
111. Zhou F, Kraehenbuhl JP, Neutra MR. Mucosal IgA response to rectally administered antigen formulated in IgA-coated liposomes. Vaccine 1995; 13:637-44.
112. Nochi T, Yuki Y, Matsumura A, Mejima M, Terahara K, Kim DY, et al. A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J Exp Med 2007; 204:2789-96.
113. Clark MA, Jepson MA, Simmons NL, Booth TA, Hirst BH. Differential expression of lectin-binding sites defines mouse intestinal M-cells. J Histochem Cytochem 1993; 41:1679-87.
114. Clark MA, Jepson MA, Simmons NL, Hirst BH. Selective binding and transcytosis of Ulex europaeus 1 lectin by mouse Peyer's patch M-cells in vivo. Cell Tissue Res 1995; 282:455-61.
115. Gupta PN, Khatri K, Goyal AK, Mishra N, Vyas SP. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J Drug Target 2007; 15:701-13.
116. Giannasca PJ, Giannasca KT, Leichtner AM, Neutra MR. Human intestinal M cells display the sialyl Lewis A antigen. Infect Immun 1999; 67:946-53.
117. Lambkin I, Pinilla C, Hamashin C, Spindler L, Russell S, Schink A, et al. Toward targeted oral vaccine delivery systems: selection of lectin mimetics from combinatorial libraries. Pharm Res 2003; 20:1258-66.
118. Misumi S, Masuyama M, Takamune N, Nakayama D, Mitsumata R, Matsumoto H, et al. Targeted delivery of immunogen to primate m cells with tetragalloyl lysine dendrimer. J Immunol 2009; 182:6061-70.
119. Pielage JF, Cichon C, Greune L, Hirashima M, Kucharzik T, Schmidt MA. Reversible differentiation of Caco-2 cells reveals galectin-9 as a surface marker molecule for human follicle-associated epithelia and M cell-like cells. Int J Biochem Cell Biol 2007; 39:1886-901.
120. Peppoloni S, Ruggiero P, Contorni M, Morandi M, Pizza M, Rappuoli R, et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev Vaccines 2003; 2:285-93.
121. Takahashi I, Nochi T, Yuki Y, Kiyono H. New horizon of mucosal immunity and vaccines. Curr Opin Immunol 2009; 21:352-8.